Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nitric Oxide in the news, again

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Feb 04, 2022 3:46pm

293 Views

Post# 34399269

Nitric Oxide in the news, again

Inhaled Nitric Oxide Can Kill COVID-Causing Coronavirus, Prevent Its Attachment to Human Cells: Indian Researchers
By IANS12 hours agoTWC India
“A study involving doctors and scientists has found that inhaled Nitric Oxide (iNO) is virucidal and kills the SARS-CoV-2 virus, while also preventing its effective attachment to human host cells.
The study was done by doctors of the Amrita Hospital in Kochi, and scientists from the School of Biotechnology at Amrita Vishwa Vidyapeetham.”

https://weather.com/en-IN/india/coronavirus/news/2022-02-04-inhaled-nitric-oxide-can-kill-covid19-causing-coronavirus

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale